Charlotte Hagedorn Jørgensen joins the DanCann Pharma team as the Company's Head of Quality Assurance. She is an experienced quality management professional and will oversee implementing relevant quality systems according to global standards such as GMP and GDP.

Charlotte Hagedorn Jørgensen has a proven track record within Quality Assurance and joins DanCann Pharma from a job as qualified person at Mezina A/S. She has more than 20 years of experience from working with GMP, GDP and general pharmaceutical issues. Charlotte Hagedorn Jørgensen has on several occasions been the driving force behind startups, which have developed into international successes within the pharma-industry such as 2Care4 ApS. Her entrepreneurial spirit and huge ambitions to make a difference will be a significant asset for DanCann Pharma. She is looking forward to her participation in the development of DanCann Pharma as an important contributor on the Danish and international markets.  

Charlotte Hagedorn Jørgensen explains:

- DanCann Pharma is a young and ambitious company with a very dedicated team of employees. When I got the opportunity, it was an easy decision for me to join and be part of the Company. The next period will consist of several important milestones and fortunately I can contribute with my track-record, expertise, and knowledge regarding various quality related issues. I am a dedicated entrepreneur and very proud to be a part of the DanCann Pharma team who share such a strong passion for improving quality of life for patients with challenges. I look forward to the exciting times ahead.

Sarah Mai Lykke-Kjeldsen , COO at DanCann Pharma elaborates:

- Charlottes know-how and experience with GMP, GDP and Quality Assurance will be an essential asset for DanCann Pharma and will help us take a huge step towards fulfilling our ambitions of having a state-of-the-art organization with second to none facilities and employees. Quality assurance is essential in reaching our goals and we are very excited about the appointment of Charlotte as head of this department. I look very much forward to working closely with her.

Charlotte Hagedorn Jørgensen will start at DanCann Pharma on the 2nd of September 2022.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.